Cohance Pashamylaram Plant Gets USFDA VAI Classification
On 7 November 2026, Cohance Lifesciences said the USFDA classified its Pashamylaram, Hyderabad plant as VAI, formally closing the July-August inspection.
On 7 November 2026, Cohance Lifesciences said the USFDA classified its Pashamylaram, Hyderabad plant as VAI, formally closing the July-August inspection.
Aurobindo Pharma’s Q2 FY27 net profit rose 32.5% to ₹1,124 crore as revenue hit a record ₹10,263 crore on US and Europe growth and 12 USFDA approvals.
Lupin’s Q2 FY27 sales rose 14% to ₹7,785.5 crore, but net profit fell 22% to ₹1,155.3 crore as its EBITDA margin narrowed 770 basis points to 27.9%.
Granules India’s Q2 FY27 net profit rose 39% to ₹182 crore on 20% revenue growth, with three first-to-file ANDAs and five US launches lined up.
Lupin has won USFDA approval for generic amifampridine 10 mg tablets to treat Lambert-Eaton myasthenic syndrome, with 180-day shared generic exclusivity.
Gland Pharma wins USFDA approval for generic Methylprednisolone Acetate Injectable Suspension, equal to Pfizer’s Depo-Medrol, a USD 214 million US market.
Dr Reddy’s wins USFDA tentative approval under PEPFAR for generic twice-yearly lenacapavir for HIV prevention, with first supplies due before end-2026.
Alkem Laboratories’ Mandva API facility cleared a five-day USFDA inspection (26–30 October 2026) with no Form 483 observations, a cleaner result than the site’s 2023 audit.
OneSource Specialty Pharma has received a USFDA EIR with VAI classification for its Bengaluru Sterile Product Division, closing the June 2026 inspection.
The USFDA issued a Form 483 with 11 observations to Granules India’s Gagillapur finished dosage plant, its first inspection since the February 2025 Warning Letter; the company says supply is unaffected.
The USFDA has classified Dr. Reddy’s FTO-SEZ Process Unit-02 in Srikakulam, Andhra Pradesh, as Voluntary Action Indicated and closed the inspection, three months after a pre-approval and GMP audit ended with a Form 483 carrying three observations.
About 17% of USFDA inspections at Indian pharma facilities now end with an Official Action Indicated classification, up from 11% in 2024, India Ratings says, warning that tougher scrutiny could delay approvals as US sales of Indian drugmakers soften.
Alembic Pharmaceuticals, one of India’s leading vertically integrated pharmaceutical companies, has announced a significant regulatory milestone with the final approval […]